European Society for Medical Oncology

Type: Organization
Name: European Society for Medical Oncology
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Eisai to present cancer drug data at ESMO 2014

:11 in Pharmaceutical Company Product News Eisai has announced that it will be presenting nine abstracts from its oncology portfolio at the 2014 European Society for Medical Oncology (ESMO) congress next week. The conference, which runs from September ... [Published Zenopa - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

--Data to be Presented at European Society for Medical Oncology Congress in Madrid--. FOSTER CITY, Calif.---- Gilead Sciences, Inc. today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, ... [Published CNBC - Sep 17 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Ignyta to Present RXDX-101 Phase I Data at 2014 ESMO Congress

Ignyta said that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion ... [Published Individual.com - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Novartis to present cancer drug data at ESMO 2014

:16 in Pharmaceutical Company Product News Novartis has announced that it will be attending the forthcoming 2014 European Society for Medical Oncology (ESMO) congress, where it will share data on its latest cancer drug developments. Taking place in Madrid ... [Published Zenopa - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

PharmaMar will be present at the 39th Congress of the European Society for Medical Oncology (ESMO 2014) with eight studies

PharmaMar will be present at the 39thMadrid, 17 September 2014 PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based ... [Published Noodls - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that cobimetinib, an Exelixis-discovered compound, will be the subject of a clinical data presentation at the European Society for Medical Oncology (ESMO) 2014 ... [Published Business Wire Health News - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 3 reports

Ignyta Announces RXDX-101 Phase I Data Presentation at the 2014 ESMO Congress

SAN DIEGO--(EON: Enhanced Online News)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary ... [Published EON Science - Sep 15 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Endocyte Surges On Upgrades

Page 1 of 2Published: September 10, 2014 at 12:17 pm EST By: Click Ticker to See live coverageEndocyte, Inc. ( ECYT ) stock surged over 17% during trading yesterday, followed by a 2.6% gain in pre-market trading today, after analysts at Cantor Fitzgerald ... [Published Bidness Etc - Sep 10 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress

REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology ... [Published PR Newswire: Health - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

OncoSec Medical to Present Data at ESMO 2014 Congress

OncoSec Medical Inc. (OTCQB: ONCS ), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and pre-clinical studies at the European Society for Medical Oncology (ESMO)Click to Continue » ... [Published Fort Mills Times - Sep 09 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Puma Biotechnology Reports European Society for Medical Oncology Presentation

Puma Biotechnology reported that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral ... [Published Individual.com - Sep 08 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Kiss of Death for Cancer Research?

David J. Kerr, CBE, MD, DSc, FRCP, FMedSciDisclosures August 25, 2014Hi. I am David Kerr, Professor of Cancer Medicine at the University of Oxford in the United Kingdom. Today I want to talk about unintended consequences.You may know that Great Britain, ... [Published American Journal of Public Health - Aug 25 2014]

Quotes

...trally-acting kappa agonist molecules," said Stephen K Doberstein, Ph D , senior vice president and chief scientific officer of Nektar Therapeutics. "With this research, we are continuing to capitalize on the ability of our small molecule polymer medicinal chemistry platform to create new peripherally-acting molecules that could address different pain conditions."
"ESMO 2012 set the standard for what a congress should be: deep, comprehensive, and up-to-the-minute" he added. "ESMO 2014 will raise that standard to a new level."
Norbert Bischofberger, Gilead’s chief scientific officer, said: "Although simtuzumab did not provide clinical benefit in difficult-to-treat advanced pancreatic cancer patients in this study, we continue to explore simtuzumab in other areas of unmet medical need.”"
...Gary Hendler, president and chief executive officer for Eisai in Europe, said: "Eisai is committed to the provision of a range of options to help reduce the significant burden of cancer for patients, their families and healthcare systems." The company applied for EU and US regulatory approval of lenvatinib as a treatment for progressive radioiodine-refractory differentiated thyroid cancer...

More Content

All (65) | News (52) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Nektar Presents Positive Preclinical Data on Ka... [Published BioMedReports - Sep 20 2014]
Merrimack Pharmaceuticals to Present Clinical a... [Published GlobeNewswire: Advertising News - Sep 19 2014]
Pancreatic Cancer Drug Simtuzumab Fails Mid-Sta... [Published PT Community - Sep 18 2014]
What's Hot at ESMO 2014 [Published American Journal of Public Health - Sep 18 2014]
Gilead's simtuzumab fails pancreatic cancer trial [Published PMLive - Sep 18 2014]
Eisai to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 18 2014]
Tunnah’s musings: Taking the medical congress b... [Published pharmaphorum - Sep 18 2014]
Exelixis to present cobimetinib phase 3 coBRIM ... [Published PharmaBiz - Sep 18 2014]
Ignyta to Present RXDX-101 Phase I Data at 2014... [Published Individual.com - Sep 18 2014]
Flexion Therapeutics Announces Clinical Hold Of... [Published BioMedReports - Sep 18 2014]
ONCOSEC MEDICAL : to Present Data at ESMO 2014 ... [Published 4 Traders - Sep 17 2014]
Gilead’s Pancreatic Cancer Drug Disappoints [Published Bidness Etc - Sep 17 2014]
OncoMed to Present New and Emerging Data From D... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
Gilead's simtuzumab fails pancreatic cancer trial [Published Pharma Times - Sep 17 2014]
Novartis to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 17 2014]
Gilead Announces Data From Phase 2 Study of Sim... [Published CNBC - Sep 17 2014]
Exelixis Announces Cobimetinib Phase 3 coBRIM R... [Published Investor's Business Daily - Sep 17 2014]
Roche to present latest oncology advances durin... [Published European Pharmaceutical Review - Sep 17 2014]
PharmaMar will be present at the 39th Congress ... [Published Noodls - Sep 17 2014]
ROCHE BEARER SHARE : to present latest oncology... [Published 4 Traders - Sep 17 2014]
Novartis presents oncology research advances wi... [Published Nasdaq - Sep 17 2014]
Exelixis Announces Cobimetinib Phase 3 coBRIM R... [Published Business Wire Health News - Sep 17 2014]
New Halaven (Eribulin) and Lenvatinib Data to b... [Published FinanzNachrichten.de - Sep 17 2014]
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Investor's Business Daily - Sep 15 2014]
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published EON Science - Sep 15 2014]
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Scottrade - Sep 15 2014]
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Science: Science News - Sep 15 2014]
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Health News - Sep 15 2014]
Agendia Test for Molecular Subtyping of Breast ... [Published Yahoo! Finance - Sep 15 2014]
Gastric Cancer: Perioperative Chemotherapy Impr... [Published Oncology Times - Sep 13 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Exelixis Announces Cobimetinib Phase 3 coBRIM R... [Published Business Wire Health News - Sep 17 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that cobimetinib, an Exelixis-discovered compound, will be the subject of a clinical data presentation at the European Society for Medical Oncology (ESMO) 2014 ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published EON Science - Sep 15 2014]
SAN DIEGO--(EON: Enhanced Online News)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Science: Science News - Sep 15 2014]
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Health News - Sep 15 2014]
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral ...
Genomic Health Announces Presentation of Positi... [Published PR Newswire: Health - Sep 09 2014]
REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology ...
1 2

Press Releases

sort by: Date | Relevance
Merrimack Pharmaceuticals to Present Clinical a... [Published GlobeNewswire: Advertising News - Sep 19 2014]
OncoMed to Present New and Emerging Data From D... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
Karyopharm Announces Three Clinical Data Presen... [Published GlobeNewswire: Acquisitions News - Sep 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.